Overview

Comparison of HR011408 and NovoRapid® in Subjects With Diabetics

Status:
RECRUITING
Trial end date:
2024-07-15
Target enrollment:
Participant gender:
Summary
The objective of the study is to compare the pharmacokinetics and pharmacodynamics between HR011408 and NovoRapid® in Subjects with Diabetics.
Phase:
PHASE1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Insulin Aspart